Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The usefulness of echocardiography in the surgical management of infants with congenital heart disease.

Clinical cardiology·1992
Same author

Giant thoracoabdominal lymphangioma with features of lymphangiomyoma.

Chest·1992
Same author

Sex differences in gastric alcohol dehydrogenase activity in Sprague-Dawley rats.

Gastroenterology·1992
Same author

Idiopathic inflammatory myopathy: clinicopathological observations in the Indian population.

British journal of rheumatology·1992
Same author

Diagnosis of the sinus venosus defect by echocardiography and angiocardiography.

Indian heart journal·1992
Same author

Pulmonary alveolar microlithiasis--report of three cases with pulmonary function and exercise studies.

The Indian journal of chest diseases & allied sciences·1992

Related Experiment Video

Updated: Jul 6, 2026

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

Antiarrhythmic drugs: present and future.

S Sharma1

  • 1Bombay Hospital and Medical Research Centre, Mumbai.

The Journal of the Association of Physicians of India
|March 29, 2008
PubMed
Summary

Catheter ablation and implantable cardioverter defibrillators (ICDs) have transformed cardiac arrhythmia treatment. Research focuses on developing new antiarrhythmic drugs with amiodarone

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Cardiac arrhythmia treatment has evolved with catheter ablation and implantable cardioverter defibrillators (ICDs).
  • Antiarrhythmic drugs are often used adjunctively with devices or for specific arrhythmia types.
  • Current drug therapies include amiodarone, sotalol, and other Vaughan Williams class agents.

Purpose of the Study:

  • To review the current landscape of antiarrhythmic drug therapy.
  • To highlight the limitations and toxicities associated with long-term amiodarone use.
  • To discuss the development of novel antiarrhythmic agents with improved safety profiles.

Main Methods:

  • Literature review of antiarrhythmic drug classifications and clinical applications.
  • Analysis of current treatment paradigms for cardiac arrhythmias.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes
09:17

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes

Published on: August 9, 2022

Related Experiment Videos

Last Updated: Jul 6, 2026

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes
09:17

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes

Published on: August 9, 2022

  • Discussion of emerging antiarrhythmic drug candidates.

    • Main Results:

    • Amiodarone remains a widely used antiarrhythmic despite significant non-cardiac toxicity.
    • Existing drug classes (II, III, IV) and sotalol are frequently employed.
    • Newer agents, such as azimilide, are under development to offer amiodarone-like efficacy without its drawbacks.

    Conclusions:

    • Advanced therapies like ablation and ICDs have shifted the role of antiarrhythmic drugs.
    • There is a critical need for safer and more effective antiarrhythmic medications.
    • Ongoing research aims to develop drugs with improved pharmacokinetic profiles and reduced toxicity.